Symbols / LRMR $4.42 +0.45%
LRMR Chart
About
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 457.87M |
| Enterprise Value | 205.51M | Income | -132.00M | Sales | — |
| Book/sh | 1.62 | Cash/sh | 2.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 65 | IPO | — |
| P/E | — | Forward P/E | -2.40 | PEG | — |
| P/S | — | P/B | 2.72 | P/C | — |
| EV/EBITDA | -1.47 | EV/Sales | — | Quick Ratio | 3.91 |
| Current Ratio | 4.06 | Debt/Eq | 3.13 | LT Debt/Eq | — |
| EPS (ttm) | -1.96 | EPS next Y | -1.84 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 | ROA | -42.99% |
| ROE | -78.24% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 103.59M |
| Shs Float | 51.16M | Short Float | 10.27% | Short Ratio | 0.96 |
| Short Interest | — | 52W High | 6.42 | 52W Low | 1.61 |
| Beta | 0.96 | Avg Volume | 4.17M | Volume | 658.68K |
| Target Price | $16.60 | Recom | Strong_buy | Prev Close | $4.40 |
| Price | $4.42 | Change | 0.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.60
Mean price target
2. Current target
$4.38
Latest analyst target
3. DCF / Fair value
$-8.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.38
Low
$7.00
High
$26.00
Mean
$16.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-03 | main | Wedbush | Outperform → Outperform | $12 |
| 2026-02-25 | main | Citigroup | Buy → Buy | $14 |
| 2026-02-25 | reit | Wedbush | Outperform → Outperform | $11 |
| 2025-10-02 | main | Oppenheimer | Outperform → Outperform | $21 |
| 2025-09-30 | main | Wedbush | Outperform → Outperform | $11 |
| 2025-09-30 | main | Baird | Outperform → Outperform | $7 |
| 2025-08-19 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2025-08-15 | main | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2025-06-25 | reit | Guggenheim | Buy → Buy | $26 |
| 2025-06-24 | main | Wedbush | Outperform → Outperform | $15 |
| 2025-06-24 | reit | Guggenheim | Buy → Buy | $26 |
| 2025-03-25 | reit | Guggenheim | Buy → Buy | $26 |
| 2025-03-25 | main | Baird | Outperform → Outperform | $10 |
| 2025-03-25 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-01-29 | init | Truist Securities | — → Buy | $18 |
| 2025-01-24 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
- Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 8% - Should You Sell? - MarketBeat hu, 12 Mar 2026 18
- LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Yahoo Finance Fri, 06 Mar 2026 08
- Larimar Therapeutics prices $60M stock offering - MSN ue, 17 Mar 2026 17
- Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative ue, 03 Mar 2026 08
- Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan Wed, 04 Mar 2026 08
- Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha Fri, 16 Jan 2026 08
- Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail ue, 10 Mar 2026 20
- Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest - MarketBeat Mon, 16 Mar 2026 11
- Rare-disease biotech Larimar seeks $75M to fund key drug - Stock Titan Wed, 25 Feb 2026 08
- Insider Purchase: Director at $LRMR Buys 2,000,000 Shares - Quiver Quantitative ue, 03 Mar 2026 01
- Larimar stock surges on FDA breakthrough status (LRMR:NASDAQ) - Seeking Alpha ue, 24 Feb 2026 08
- Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat Sat, 14 Mar 2026 11
- Deerfield funds boost Larimar Therapeutics (LRMR) stake with 5M-share open-market buy - Stock Titan Mon, 02 Mar 2026 08
- $LRMR stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Wed, 05 Nov 2025 08
- Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat Fri, 13 Mar 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000 | 25000 | — | Purchase at price 5.00 per share. | SHERMAN JEFFREY W | Director | — | 2026-02-27 00:00:00 | D |
| 1 | 5000 | 25000 | — | Purchase at price 5.00 per share. | THOMAS FRANK E | Director | — | 2026-02-27 00:00:00 | D |
| 2 | 5000000 | 25000000 | — | Purchase at price 5.00 per share. | FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-27 00:00:00 | I |
| 3 | 100000 | 500000 | — | Purchase at price 5.00 per share. | HAMILTON THOMAS EDWARD | Director | — | 2026-02-27 00:00:00 | D |
| 4 | 100100 | — | — | Stock Award(Grant) at price 0.00 per share. | BEN MAIMON CAROLE S | Chief Executive Officer | — | 2026-01-26 00:00:00 | D |
| 5 | 37604 | — | — | Stock Award(Grant) at price 0.00 per share. | CELANO MICHAEL | Chief Financial Officer | — | 2026-01-26 00:00:00 | D |
| 6 | 25637 | — | — | Stock Award(Grant) at price 0.00 per share. | CLAYTON RUSSELL | Officer | — | 2026-01-26 00:00:00 | D |
| 7 | 25637 | — | — | Stock Award(Grant) at price 0.00 per share. | SHANKAR GOPI | Officer | — | 2026-01-26 00:00:00 | D |
| 8 | 9375000 | 30000000 | — | Purchase at price 3.20 per share. | FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-31 00:00:00 | I |
| 9 | 91000 | — | — | Stock Award(Grant) at price 0.00 per share. | BEN MAIMON CAROLE S | Chief Executive Officer | — | 2025-01-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -90.57M | -41.45M | -36.21M | -50.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -80.60M | -36.95M | -35.35M | -50.64M |
| ReconciledDepreciation | 318.00K | 311.00K | 318.00K | 326.00K |
| EBITDA | -90.57M | -41.45M | -36.21M | -50.14M |
| EBIT | -90.89M | -41.76M | -36.53M | -50.47M |
| NormalizedIncome | -80.60M | -36.95M | -35.35M | -50.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -80.60M | -36.95M | -35.35M | -50.64M |
| TotalExpenses | 90.89M | 41.76M | 36.53M | 50.47M |
| TotalOperatingIncomeAsReported | -90.89M | -41.76M | -36.53M | -50.47M |
| DilutedAverageShares | 61.26M | 43.90M | 25.76M | 17.16M |
| BasicAverageShares | 61.26M | 43.90M | 25.76M | 17.16M |
| DilutedEPS | -1.32 | -0.84 | -1.37 | -2.95 |
| BasicEPS | -1.32 | -0.84 | -1.37 | -2.95 |
| DilutedNIAvailtoComStockholders | -80.60M | -36.95M | -35.35M | -50.64M |
| NetIncomeCommonStockholders | -80.60M | -36.95M | -35.35M | -50.64M |
| NetIncome | -80.60M | -36.95M | -35.35M | -50.64M |
| NetIncomeIncludingNoncontrollingInterests | -80.60M | -36.95M | -35.35M | -50.64M |
| NetIncomeContinuousOperations | -80.60M | -36.95M | -35.35M | -50.64M |
| PretaxIncome | -80.60M | -36.95M | -35.35M | -50.64M |
| OtherIncomeExpense | 10.29M | 4.81M | 1.17M | -171.00K |
| OtherNonOperatingIncomeExpenses | 10.29M | 4.81M | 1.17M | -171.00K |
| OperatingIncome | -90.89M | -41.76M | -36.53M | -50.47M |
| OperatingExpense | 90.89M | 41.76M | 36.53M | 50.47M |
| ResearchAndDevelopment | 73.28M | 27.67M | 24.25M | 38.40M |
| SellingGeneralAndAdministration | 17.61M | 14.09M | 12.28M | 12.07M |
| GeneralAndAdministrativeExpense | 17.61M | 14.09M | 12.28M | 12.07M |
| OtherGandA | 17.61M | 14.09M | 12.28M | 12.07M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 63.82M | 43.91M | 43.27M | 17.71M |
| ShareIssued | 63.82M | 43.91M | 43.27M | 17.71M |
| TotalDebt | 5.12M | 5.55M | 5.41M | 6.00M |
| TangibleBookValue | 171.81M | 81.72M | 110.90M | 64.41M |
| InvestedCapital | 171.81M | 81.72M | 110.90M | 64.41M |
| WorkingCapital | 170.95M | 80.67M | 110.03M | 63.36M |
| NetTangibleAssets | 171.81M | 81.72M | 110.90M | 64.41M |
| CapitalLeaseObligations | 5.12M | 5.55M | 5.41M | 6.00M |
| CommonStockEquity | 171.81M | 81.72M | 110.90M | 64.41M |
| TotalCapitalization | 171.81M | 81.72M | 110.90M | 64.41M |
| TotalEquityGrossMinorityInterest | 171.81M | 81.72M | 110.90M | 64.41M |
| StockholdersEquity | 171.81M | 81.72M | 110.90M | 64.41M |
| GainsLossesNotAffectingRetainedEarnings | 148.00K | 81.00K | -31.00K | 0.00 |
| OtherEquityAdjustments | 148.00K | 81.00K | -31.00K | |
| RetainedEarnings | -269.16M | -188.55M | -151.60M | -116.25M |
| AdditionalPaidInCapital | 440.76M | 270.15M | 262.50M | 180.65M |
| CapitalStock | 64.00K | 43.00K | 43.00K | 18.00K |
| CommonStock | 64.00K | 43.00K | 43.00K | 18.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 28.41M | 14.21M | 15.50M | 14.25M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.06M | 4.71M | 4.80M | 5.41M |
| LongTermDebtAndCapitalLeaseObligation | 4.06M | 4.71M | 4.80M | 5.41M |
| LongTermCapitalLeaseObligation | 4.06M | 4.71M | 4.80M | 5.41M |
| CurrentLiabilities | 24.36M | 9.51M | 10.71M | 8.85M |
| CurrentDebtAndCapitalLeaseObligation | 1.06M | 837.00K | 611.00K | 594.00K |
| CurrentCapitalLeaseObligation | 1.06M | 837.00K | 611.00K | 594.00K |
| PayablesAndAccruedExpenses | 23.30M | 8.67M | 10.09M | 8.25M |
| CurrentAccruedExpenses | 20.87M | 7.39M | 8.41M | 6.59M |
| Payables | 2.42M | 1.28M | 1.69M | 1.66M |
| AccountsPayable | 2.42M | 1.28M | 1.69M | 1.66M |
| TotalAssets | 200.22M | 95.94M | 126.41M | 78.67M |
| TotalNonCurrentAssets | 4.92M | 5.76M | 5.67M | 6.46M |
| OtherNonCurrentAssets | 1.20M | 2.00M | 1.98M | 2.01M |
| NetPPE | 3.72M | 3.76M | 3.69M | 4.46M |
| AccumulatedDepreciation | -1.54M | -1.23M | -914.00K | -596.00K |
| GrossPPE | 5.26M | 4.99M | 4.60M | 5.05M |
| Leases | 45.00K | 45.00K | 31.00K | 31.00K |
| OtherProperties | 4.54M | 4.27M | 4.05M | 4.50M |
| MachineryFurnitureEquipment | 672.00K | 672.00K | 522.00K | 522.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 195.30M | 90.17M | 120.74M | 72.20M |
| OtherCurrentAssets | 517.00K | 377.00K | 238.00K | 279.00K |
| PrepaidAssets | 10.28M | 2.68M | 2.07M | 1.62M |
| Receivables | 1.05M | 332.00K | 0.00 | 208.00K |
| TaxesReceivable | 0.00 | 208.00K | ||
| AccruedInterestReceivable | 1.05M | 332.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 183.45M | 86.79M | 118.43M | 70.10M |
| OtherShortTermInvestments | 150.24M | 60.04M | 91.60M | 0.00 |
| CashAndCashEquivalents | 33.22M | 26.75M | 26.82M | 70.10M |
| CashEquivalents | 26.70M | 24.70M | 22.18M | 14.90M |
| CashFinancial | 6.52M | 2.05M | 4.64M | 55.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -71.28M | -33.62M | -27.67M | -42.44M |
| IssuanceOfCapitalStock | 161.81M | 0.00 | 75.26M | 19.89M |
| CapitalExpenditure | -515.00K | -164.00K | -100.00K | -333.00K |
| EndCashPosition | 33.82M | 28.09M | 28.16M | 71.44M |
| BeginningCashPosition | 28.09M | 28.16M | 71.44M | 69.49M |
| ChangesInCash | 5.74M | -76.00K | -43.27M | 1.95M |
| FinancingCashFlow | 161.88M | 30.00K | 75.26M | 19.89M |
| CashFlowFromContinuingFinancingActivities | 161.88M | 30.00K | 75.26M | 19.89M |
| ProceedsFromStockOptionExercised | 77.00K | 30.00K | 0.00 | |
| NetCommonStockIssuance | 161.81M | 0.00 | 75.26M | 19.89M |
| CommonStockIssuance | 161.81M | 0.00 | 75.26M | 19.89M |
| InvestingCashFlow | -85.39M | 33.35M | -90.96M | 24.17M |
| CashFlowFromContinuingInvestingActivities | -85.39M | 33.35M | -90.96M | 24.17M |
| NetInvestmentPurchaseAndSale | -84.87M | 33.52M | -90.86M | 24.50M |
| SaleOfInvestment | 143.00M | 134.75M | 42.75M | 32.75M |
| PurchaseOfInvestment | -227.87M | -101.23M | -133.61M | -8.25M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -515.00K | -164.00K | -100.00K | -333.00K |
| PurchaseOfPPE | -515.00K | -164.00K | -100.00K | -333.00K |
| OperatingCashFlow | -70.76M | -33.46M | -27.57M | -42.10M |
| CashFlowFromContinuingOperatingActivities | -70.76M | -33.46M | -27.57M | -42.10M |
| ChangeInWorkingCapital | 6.17M | -2.51M | 1.67M | 2.73M |
| ChangeInOtherCurrentLiabilities | -515.00K | |||
| ChangeInOtherCurrentAssets | 63.00K | -21.00K | 31.00K | -250.00K |
| ChangeInPayablesAndAccruedExpense | 14.58M | -1.43M | 1.84M | -225.00K |
| ChangeInAccruedExpense | 13.44M | -1.02M | 1.82M | 749.00K |
| ChangeInPayable | 1.14M | -403.00K | 26.00K | -974.00K |
| ChangeInAccountPayable | 1.14M | -403.00K | 26.00K | -974.00K |
| ChangeInPrepaidAssets | -8.46M | -1.06M | -204.00K | 3.21M |
| OtherNonCashItems | -189.00K | -82.00K | -46.00K | 15.00K |
| StockBasedCompensation | 8.80M | 7.62M | 6.62M | 5.47M |
| AmortizationOfSecurities | -5.26M | -1.84M | -774.00K | -14.00K |
| DepreciationAmortizationDepletion | 318.00K | 311.00K | 318.00K | 326.00K |
| DepreciationAndAmortization | 318.00K | 311.00K | 318.00K | 326.00K |
| Depreciation | 318.00K | 311.00K | 318.00K | 326.00K |
| OperatingGainsLosses | -1.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -1.00K | ||
| NetIncomeFromContinuingOperations | -80.60M | -36.95M | -35.35M | -50.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LRMR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|